Efficacy and safety of Bosutinib in Patient with Chronic myeloid
leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report
- Abdullah Mohammad Arshad
, - mohamed yassin
Abstract
Bosutinib is approved as first line therapy for treatment of chronic
phase CML and also in patients who are either resistant or intolerant to
previous TKI. We present a 59 year old male who was intolerant to 2 TKI
but showed excellent hematological and major molecular response to
Bosutinib.
